Nutrilipid is exclusively used for nutritional intervention when the digestive system cannot provide necessary sustenance, applied across domains involving severe metabolic and deficiency states. It is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition (PN).

---

What Nutrilipid Treats: Main Uses and Benefits

Addressing Severe Caloric Deficit and Body Wasting

This therapeutic domain focuses on managing the consequences associated with severe systemic energy depletion and loss of body mass. Nutrilipid provides a concentrated source of energy and essential lipids, offering support that generally assists with the management of body wasting and mass depletion during acute critical illness, such as following major trauma or sepsis. It provides necessary nutritional support when oral or enteral feeding is compromised, such as in cases of chronic intestinal failure or those requiring prolonged bowel rest.

Addressing Manifestations of Essential Fatty Acid Deficiency (EFAD)

This intravenous product is relevant for the prevention and management of the clinical manifestations associated with a lack of vital lipids the body cannot synthesize itself. This is relevant for managing symptoms such as scaly skin, poor wound healing, hair loss, and growth failure in children. By assisting with complete nutritional support, it supports the patient during these difficult episodes.

---

Quick Fact: Support for Nutritional Deficit Symptoms (wasting, poor healing)

Regulatory References

1. NIH DailyMed entry for Nutrilipid

Eligibility: Who Can and Cannot Use Nutrilipid?

The use of Nutrilipid is determined by official regulatory criteria, primarily based on patient sensitivity and metabolic status.

Contraindication	Population / Condition
Absolute Prohibition	Patients with known hypersensitivity to egg, soybean, or peanut proteins, or any component of the emulsion.
Severe Hyperlipidemia	Patients with severe disorders of lipid metabolism, specifically hypertriglyceridemia characterized by serum triglyceride levels greater than 1,000 mg/dL.

---

Populations Requiring Caution and Restrictions

Nutrilipid is approved for use in adults, pediatric patients, and infants. However, specific patient groups require conditional use and close monitoring:

• Infants (Preterm and SGA): Use is established but subject to a Warning due to the poor clearance of intravenous lipid emulsion and the risk of death if the infusion is administered too rapidly.
• Organ Impairment: Patients with impaired hepatic function must be monitored closely due to the risk of Parenteral Nutrition-Associated Liver Disease (PNALD). Those with impaired renal function are at an increased risk of Aluminum Toxicity.
• Geriatric Patients: Clinical studies did not include sufficient data to determine if responses in patients aged 65 and over differ from younger adults.

Pregnancy and Lactation Status

There are no adequate or well-controlled studies in pregnant women, meaning the risk is unknown. It should only be used if the potential benefit justifies the potential risk. It is unknown if the medicine is present in human milk, and caution is advised for nursing women.

Interactions with other medicines and products

This section describes officially documented interaction patterns and restrictions for this intravenous fat emulsion, strictly as defined in government regulatory labeling.

Pharmacodynamic and Metabolic Interactions

The product contains Vitamin K1, which can lead to the counteraction of anticoagulant activity when co-administered with medicines in the class of coumarin and coumarin derivatives, including warfarin. Regulatory labeling explicitly requires the monitoring of coagulation laboratory parameters due to this significant pharmacodynamic effect. Use is formally contraindicated in patients with severe hyperlipidemia or other severe disorders of lipid metabolism where serum triglyceride concentrations exceed 1000 mg/dL. Contraindication also applies to patients with known hypersensitivity to egg or soybean proteins.

Procedural and Physical Constraints

Regulatory documentation defines two critical administrative constraints:

• Procedural Timing: A separation window is required for diagnostics. To prevent interference from circulating lipids, the label states that blood samples for certain laboratory tests must not be drawn until at least five to six hours after the cessation of the infusion.
• Physical Incompatibility: The emulsion is subject to physical destabilization when mixed in an admixture with substances that create excessive acidity ( pH below 5) or contain inappropriate electrolyte content, such as divalent cations ( Ca^++ and Mg^++), which are defined as prohibited physical combinations.

Enzyme-Mediated Energy Conversion and Fuel Supply

The mechanism of action for Nutrilipid is defined by its role as a metabolic substitute, supplying critical substrates directly into the systemic circulation. The emulsion delivers high-density triglycerides that function as substrates for energy metabolism. The primary step involves the enzyme Lipoprotein Lipase (LPL) which hydrolyzes the particles, releasing free fatty acids that are subsequently oxidized within the mitochondria via beta-oxidation to produce ATP. This sequence results in the generation of ATP, contributing to energy balance.

---

Structural Integration of Essential Fatty Acids

The product supplies linoleic acid (Omega-6) and alpha-linolenic acid (Omega-3), which the body cannot synthesize. These essential fatty acids are structurally integrated into the phospholipid bilayer of cell membranes. This integration maintains the correct biophysical properties of the membrane, including fluidity and permeability, which influences signal transduction.

---

Modulation of Eicosanoid Precursor Pathways

The delivered fatty acids act as precursors that influence the body's synthesis of local signaling molecules, known as eicosanoids. By providing both Omega-6 and Omega-3 precursors, the mechanism alters the precursor ratio for eicosanoid synthesis, which influences the resultant mixture of mediators that participate in systemic physiological processes, such as the regulation of local vascular tone.

How to Use Nutrilipid

Nutrilipid 20% is an intravenous fat emulsion used exclusively as a component of parenteral nutrition (PN) when patients require sustenance and essential fatty acids that cannot be delivered through the digestive system. The principles of its use are strictly defined and focus on administration route, individualized dosage, and infusion conditions.

---

Administration and Dosage Regimen

The emulsion is for intravenous infusion only and can be administered via either a peripheral or central venous line. The final dosage is individualized, calculated based on the patient's body weight and metabolic capacity. The daily lipid dose for adults typically ranges from 1 to 1.5 g/kg of lipid, with an official maximum limit of 2.5 g/kg/day. For pediatric patients, dosing is age-dependent, with specific maximum limits, such as 3 g/kg/day for preterm and term infants and 2.5 g/kg/day for children aged 1 to 10 years.

---

Procedural Administration Constraints

The daily amount of the emulsion is generally infused continuously over a period of 12 to 24 hours as part of the total nutritional regimen. Administration requires the mandatory use of a 1.2 micron in-line filter. The product is commonly co-administered with other PN solutions (amino acids and dextrose) using a Y-connector near the infusion site. The Pharmacy Bulk Package is not intended for direct infusion and requires aseptic transfer and preparation into a final admixture before use.

Research evidence / Overview of Studies for Nutrilipid

Evidence for Use in Providing Nutritional Support (Parenteral Nutrition)

This section will summarize the structure of clinical studies, including randomized controlled trials (RCTs) and observational cohorts, which examined Nutrilipid's role in supplying essential calories and nutritional support to patients who cannot eat normally. The content will detail the outcomes that researchers monitored, such as trends in body weight, lipid clearance, and metabolic markers.

Nutrilipid, an example of a soybean oil-based intravenous lipid emulsion (ILE), was evaluated in clinical trials and observational studies that research examined its role in Parenteral Nutrition (PN). These studies focused on the evaluation of a high-density source of calories and fat in the context of severe energy depletion and potential systemic or functional imbalance. Findings describe patterns observed in the studies that were consistent with the delivery of fat and energy to the body's systems, contributing to the nutritional component of PN.

Evidence for Managing Essential Fatty Acid Deficiency (EFAD)

Nutrilipid was studied for its capacity to address Essential Fatty Acid Deficiency (EFAD), a state caused by a lack of vital fats the body cannot make itself. This condition is characterized by fluctuating or episodic manifestations such as scaly skin, hair loss, and, in children, poor growth. Studies explored the use of this formulation for both preventing EFAD in high-risk patients and examining the impact on the deficiency once it appeared.

Research examined outcomes related to systemic or functional imbalance by measuring the level of essential fatty acids, such as linoleic acid and alpha-linolenic acid, in the patient’s blood. Studies monitored these biochemical markers to see how they changed after the ILE was administered.

What Remains Uncertain About the Evidence Base

Although the foundational use of soybean oil ILEs is widely referenced in nutritional support, evidence quality varies across studies, especially when comparing clinical outcomes to newer, structurally different fat emulsions. Long-term outcomes are not well characterized in large-scale studies for all patient populations. Key research limitations include the fact that many recent comparative trials have focused on evaluating the potential risks associated with traditional soybean oil ILEs, and follow-up durations were limited in acute settings.

Key Studies & References

1. Nutrilipid (Intravenous Lipid Emulsion) Injection: DailyMed - U.S. National Library of Medicine (NIH)
2. Intravenous Lipid Emulsions: An Overview
3. Parenteral nutrition: MedlinePlus Medical Encyclopedia
4. Comparison of different intravenous lipid emulsions in pediatric parenteral nutrition: A systematic review and meta-analysis

Common questions about Nutrilipid (FAQ)

Q: Is Nutrilipid the same as other IV nutrition therapies?

A: Nutrilipid is classified as an intravenous fat emulsion and serves as just one component of a patient’s overall nutritional plan, which is often called parenteral nutrition (PN). Other intravenous nutritional regimens, such as Total Parenteral Nutrition (TPN), typically incorporate the lipid emulsion along with solutions providing amino acids and dextrose to provide comprehensive support. The official product description indicates its specific role in supplying essential fats and calories.

Q: Can older adults receive Nutrilipid?

A: Nutrilipid is approved for use in adults generally. However, the official prescribing information notes that clinical studies did not include enough patients aged 65 and older to determine if their responses differ from those of younger adults. Specific patient populations, including the elderly, may be subject to closer monitoring as determined by a healthcare provider.

Q: Does Nutrilipid interact with common over-the-counter pain relievers?

A: Regulatory documents do not specifically mention interactions with common non-prescription pain relievers. A key documented drug interaction involves warfarin and related anticoagulant medicines. This is because the emulsion contains Vitamin K1, which can potentially counteract the effects of these blood thinners.

Q: Is Nutrilipid safe for pregnant or breastfeeding people?

A: Official information states that there are no adequate and well-controlled studies of the medicine in pregnant women. It is also unknown whether the medicine passes into human milk. Regulatory information states the product should only be used if the potential benefit is judged to justify the potential risk to the fetus or infant.

Q: What is the difference between Nutrilipid and total parenteral nutrition (TPN)?

A: Nutrilipid is an intravenous fat emulsion that provides fats and calories. Total Parenteral Nutrition (TPN) is the broader, comprehensive feeding method that uses an IV line to deliver the patient's entire necessary daily nutrition, typically by combining the fat emulsion (like Nutrilipid) with solutions containing amino acids and dextrose (sugars).

Q: Can Nutrilipid affect kidney function?

A: The official product information does not directly describe the medicine as the cause of kidney impairment. However, regulatory warnings specify that patients who already have impaired kidney function may be at an increased risk of aluminum toxicity during prolonged intravenous administration of nutritional products.

Q: Will using Nutrilipid change the results of my blood tests?

A: Yes, regulatory documents mention that the presence of circulating lipids in the blood can interfere with certain laboratory tests. To prevent inaccurate results, official guidelines state that blood samples for specific tests should not be drawn until at least five to six hours after the infusion has been completed.

Q: Can Nutrilipid cause problems with the liver?

A: Problems with the liver, including Parenteral Nutrition-Associated Liver Disease (PNALD), have been documented in patients receiving intravenous nutrition. Because of this risk, official labeling indicates that liver tests should be monitored as part of the treatment.

Q: Is it possible to become dependent on Nutrilipid?

A: Nutrilipid is indicated for patients who require nutritional support when they cannot receive nourishment through the mouth or digestive system. It provides necessary sustenance, but it is not classified as a controlled substance or a medicine with dependence liability in official regulatory documents.

Q: Does Nutrilipid interact with common medications for high blood pressure?

A: Official regulatory documents do not list specific interactions with common medications used to treat high blood pressure. Interactions are officially described only for the class of anticoagulants, such as warfarin, due to the presence of Vitamin K1 in the emulsion.

Q: Can patients who are allergic to eggs or soy use Nutrilipid?

A: No, the official prescribing information states that the product is contraindicated (absolutely prohibited) for patients with a known severe hypersensitivity to egg protein, soybean protein, or any component of the emulsion.

Q: What is the source of the lipids in Nutrilipid?

A: The primary active ingredient and source of the fats (lipids) is purified Soybean Oil. To create the stable emulsion, Egg Yolk Phospholipids are used as natural emulsifying agents, stabilizing the oil-in-water mixture for infusion.

Q: Can I eat or drink normally while receiving Nutrilipid?

A: The medicine is indicated for use when a patient cannot receive adequate nutrition through the mouth or digestive tract. Whether a patient is able to eat or drink normally while receiving the infusion is determined by the patient's clinical condition and the reason for requiring parenteral nutrition.

Q: Are there any religious or dietary restrictions related to Nutrilipid ingredients?

A: The official labeling does not discuss the product's components in relation to specific religious or dietary laws. However, the product is known to contain plant-derived Soybean Oil and animal-derived Egg Yolk Phospholipids, and the composition is fully described in the prescribing information.

Q: What are the signs of too much Nutrilipid being given?

A: Overdosage or the inability to clear the lipids from the blood can lead to a severe reaction known as Fat Overload Syndrome. Signs may include fever, reduced ability of the blood to clot, high concentrations of fat in the blood, and changes to the liver. Regulatory guidance suggests that monitoring of blood triglyceride levels is advisable.

How to Store and Dispose of Nutrilipid® 20%

Nutrilipid must be stored in its original container at Controlled Room Temperature of 20 C to 25 C (68 F to 77 F), with excursions up to 30 C permitted. Do not freeze the product, and keep it out of the reach of children.

Stability and Handling

Container Type	Post-Opening Storage Limit
Single-Dose Bag	Intended for immediate infusion after overwrap removal.
Pharmacy Bulk Package	Must be used for admixing within 4 hours of closure penetration.
Admixture	Max 24 hours under refrigeration (2 C to 8 C); use completely within 24 hours after removal from refrigeration.

Inspect the bag before use; do not use if the oxygen indicator is pink or dark pink or if the seals are damaged. Any unused portion of the product, along with the protective overwrap and oxygen indicator, must be discarded.